A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT00424775
Phase
PHASE1
Status
Terminated

Conditions

  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MK0683, vorinostat — DRUG
    vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.

Study Details

The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.

Key Dates

Start date
Jan 31, 2007
Status verified
Mar 2015
Primary completion
Mar 31, 2007
Completion
Mar 31, 2007

Study Design

Enrollment
3 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Number of Participants With a Dose Limited Toxicity at First Cycle [ Time Frame: 25 Days (first cycle) ]

Related Studies